Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials Rebaz M. Ali, Karukh K. Mohammed, Sasan M. Ahmed, Kayhan A. Najar, Mohammed Q. Mustafa, Zanyar K. Hama, Shadan A. Hamad, Maria A. Rasool and 4 more Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCLC) after progression on platinum-based therapy. This meta-analysis evaluated the efficacy and safety of tarlatamab as monotherapy and in combination… 2025 5,636 reads 1 citation doi:10.58742/bmj.v4i1.216 Full text PDF XML Read abstract — read the abstract for Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials Review Articles Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials Rebaz M. Ali, Karukh K. Mohammed, Sasan M. Ahmed, Kayhan A. Najar, Mohammed Q. Mustafa, Zanyar K. Hama, Shadan A. Hamad, Maria A. Rasool and 4 more IntroductionTarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCLC) after progression on platinum-based therapy. This meta-analysis evaluated the efficacy and safety of tarlatamab as monotherapy and in combination regimens in the treatment of SCLC. MethodsA systematic review and meta-analysis were conducted in accordance with PRISMA 2020 guidelines. PubMed/MEDLINE and EMBASE were searched from inception through September 2025 to identify clinical trials evaluating tarlatamab in SCLC. Eligible studies reported quantifiable efficacy and/or safety outcomes. Random-effects models were used to pool objective response rate (ORR) and disease control rate (DCR), and Kaplan–Meier methods were applied to assess survival outcomes. ResultsSeven clinical trials involving 1,247 patients with advanced SCLC were included. The pooled ORR was 0.42 (95% CI 0.31–0.54), with response rates ranging from 21–47% in monotherapy studies and up to 48% in combination regimens. Across six studies, pooled DCR was 0.48 (95% CI 0.31–0.66), with DCR reaching up to 87% in combination settings. Median progression-free survival ranged from 3.5 to 5.6 months, while median overall survival ranged from 13.2 to 25.3 months. Pooled time-to-event analyses demonstrated significant reductions in the risk of disease progression and death. Grade 3 and grade 4 adverse events occurred in 5.4% and 1.4% of patients, respectively, although safety reporting was incomplete in several studies. ConclusionTarlatamab demonstrates clinically meaningful antitumor activity with an acceptable safety profile in heavily pretreated SCLC. These findings support DLL3-targeted therapy as a promising treatment strategy and warrant further prospective studies to define its optimal role in the evolving SCLC treatment landscape. Keywords Targeted therapy · Immunotherapy · Second-line therapy · First-line therapy · Delta-like ligand 3 · Efficacy and safety All subjects Barw Medical Journal. 2025;3(5):42–51 Read the article PDF XML
